Bio Path reported $677K in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Alterity Therapeutics Limited AUD 37.91M 15.92M Dec/2025
Baxter International USD 6.85B 25M Mar/2026
Bio Path USD 677K 14K Mar/2026
Cipla INR 241.47B 7.71B Mar/2026
Clal Biotechnology ILS 14.69M 1.95M Dec/2023
Compugen USD 148.02M 59.1M Dec/2025
CSL USD 11.85B 1000K Dec/2025
Grifols EUR 5.96B 316.31M Dec/2025
Karyopharm Therapeutics USD 103.15M 13.4M Dec/2025